Sansum Diabetes Research Institute (SDRI) has appointed Dr. Andrew S. Rhinehart as its new CEO/chief scientific and medical officer, a unified leadership role designed to accelerate SDRI’s next era of scientific innovation, clinical impact, and national partnership.
SDRI is a global center of diabetes research and clinical innovation, from its pioneering history as the first U.S. provider of insulin to groundbreaking work in diabetes in pregnancy, continuous glucose monitoring, and automated insulin delivery.
“I am honored to step into this role at SDRI,” said Dr. Rhinehart. “From Dr. Sansum’s early work delivering insulin to Dr. Lois Jovanovic’s groundbreaking advances in diabetes in pregnancy, SDRI has a remarkable legacy of improving lives.
“The impact of this institute can be seen every day in the people who benefit from innovations pioneered here.”
“What excites me most is advancing meaningful innovation with our partners,” said Dr. Rhinehart. “Our Screen and Treat initiative is a powerful example, detecting type 1 diabetes earlier and connecting families with emerging prevention options can truly change lives. But that’s just one piece of the work ahead.
“Beyond that, SDRI is driving research that explores new technologies and therapies to transform care for people living with diabetes worldwide,” he said. “I’m grateful for the chance to lead this mission-driven team and help shape SDRI’s future.”
“Dr. Rhinehart brings exceptional expertise in the diabetes research and clinical arenas along with a thoughtful, forward-looking leadership style,” said Jim Sloan, president of SDRI’s Board of Trustees. “We are thrilled to welcome him into this role.”
Learn more about Sansum Diabetes Research Institute at www.sansum.org.